If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 1 - 10 of 66
A Multi-Center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects with Relapsed and/or Refractory Diffuse Large B
Objective
Phase II MB-CART2019.1 for R/R DLBCL
Protocol No
MILTENYI-MB-CART2019-1-DLBCL
Categories
A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies
Objective
A phase 1 Study evaluating NX-5948, a BTK Degrader in Adults with Relapsed Refractory B-cell Malignancies
Protocol No
NURIX-NX-5948-301
Categories
Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials
Objective
A Screening Study to Assign People with Myeloid Cancer to a Treatment Study or Standard of Care Treatment within myeloMATCH
Protocol No
SWOG-MYELOMATCH
Categories
Phase 1/1b, Open-Label, Dose-Escalation, Dose-Expansion, Parallel Assignment Study to Evaluate Safety and Clinical Activity of PBCAR0191 (Azercabtagene Zapreleucel or "Azer-cel") in Subjects with Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) a
Objective
Dose-escalation, Dose-expansion Study of Safety of PBCAR0191 in Patients With r/r NHL B-cell
Protocol No
PRECISION-PBCAR0191-01
Categories
A Measurable Residual Disease (MRD) Focused, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH Clinical Trial
Objective
Comparing cytarabine + daunorubicin therapy versus cytarabine + daunorubicin + venetoclax versus venetoclax + azacitidine in younger patients with intermediate risk AML
Protocol No
CCTG-MM1YA-CTG01
Categories
A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of IMPT-314, a CD19/20 Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy in Participants with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Objective
The purpose of this research is to find new ways to treat lymphomas that have either come back after treatment or have stopped responding to treatment.
Protocol No
IMMPACT-MPCT-012L
Categories
A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)
Objective
Prospective, Observational Study of Participants at Risk for CGVHD
Protocol No
INCYTE-MA-GVHD-401-THRIVE
Categories
A Phase 1b/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DISC-0974 in Participants with Myelofibrosis or Myelodysplastic Syndrome and Anemia
Objective
Phase 1-2 DISC-0974 in Myelofibrosis and Anemia
Protocol No
DISC-0974-102
Categories
Phase I Study of LV20.19 CAR T-Cells in Combination with Pirtobrutinib for Relapsed, Refractory B-Cell Malignancies
Objective
Phase I Study of LV20.19 CAR T-Cells in Combination with Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
Protocol No
IIT-SHAH-PIRTO
Categories
A Phase 1b/2 Study of GC012F, a Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects with Relapsed/Refractory Multiple Myeloma
Objective
Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in subjects with r/r MM
Protocol No
GRACELL-GC012F-CD19-BCMA-001